News | Radiation Therapy | January 31, 2018

Varian Signs Agreement to Acquire Sirtex

Acquisition adds Sirtex’s SIR-Spheres Y-90 resin microspheres to Varian’s interventional oncology portfolio

Varian Signs Agreement to Acquire Sirtex

January 31, 2018 — Varian Medical Systems announced it has signed an agreement to acquire all the outstanding shares of Sirtex Medical Ltd., an Australia-based global life sciences company focused on interventional oncology therapies. Sirtex is listed on the Australian Securities Exchange, for A$28 per share in cash. On a fully diluted basis, this represents a total equity purchase price for the acquisition of approximately A$1,585M (approximately US$1,283M). The acquisition has been unanimously approved by the Board of Directors of each company and the Sirtex Board of Directors has agreed to unanimously recommend that Sirtex shareholders approve the transaction, provided that an independent expert, to be retained by Sirtex, considers the transaction to be in the best interests of Sirtex shareholders and in the absence of a superior offer.

Varian said the acquisition of Sirtex, which specializes in radioembolization, expands Varian's addressable market into interventional oncology. Varian expects to leverage its capabilities in treatment planning and delivery, image guidance and processing, oncology practice management software, and radiation safety in combination with Sirtex's interventional oncology platform.

Sirtex's lead product is a targeted internal radiation therapy for certain liver cancers. Approximately 80,000 doses of SIR-Spheres Y-90 resin microspheres have been supplied to treat patients with liver cancer at more than 1,090 medical centers in over 40 countries. It has premarket approval (PMA) from the U.S. Food & Drug Administration (FDA), the European Union (CE Mark) and Australia's Therapeutic Goods Administration (TGA). Sirtex has manufacturing capabilities in the United States, Singapore and Germany.

Sirtex generated annual revenues of A$234mm in the fiscal year ended June 30, 2017. Sirtex has approximately 300 employees worldwide and maintains sales and distribution operations primarily in the United States, Europe and Asia.

For more information: www.varian.com, www.sirtex.com

 

Related Content

Hippocampal Sparing Prevents Whole-Brain Radiotherapy Cognitive Side Effects
News | Radiation Therapy | October 23, 2018
Whole-brain radiotherapy can be delivered more safely to patients with brain metastases by avoiding the hippocampus,...
News | Prostate Cancer | October 22, 2018
The first report of a large, international clinical trial shows that, for men who show signs of...

Image courtesy of Vital Images

News | ASTRO | October 22, 2018
Treatment of renal cell carcinoma with stereotactic radiation therapy is as safe and effective for patients with one
DCIS, ductal carcinoma in situ, radiation therapy, survival benefit, Brigham and Women's Hospital study

Image courtesy of Barco

News | ASTRO | October 21, 2018
A subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservatio
The Aquilion Precision CT system from Canon offers very high resolution imaging, which may aid in cancer detection and improved treatment planning in radiation oncology. #ASTRO2018 #ASTRO #ASTRO18

The Aquilion Precision CT system from Canon offers very high resolution imaging, which may aid in cancer detection and improved treatment planning in radiation oncology. 

News | Computed Tomography (CT) | October 19, 2018
October 19, 2018 – At the 2018 American Society of...
IBA's Proteus system and proton therapy solutions will be discussed at ASTRO 2018. #ASTRO18 #ASTRO #ASTRO2018
News | Proton Therapy | October 19, 2018
October 19, 2018 – IBA (Ion Beam Applications S.A.) is sharing how hospitals can secure performance, investment and t
Videos | Interventional Radiology | October 19, 2018
Scott Schwartz, M.D., interventional radiologist and program director for IR residencies and the vascular and interve
IBA Dosimetry Enters Interoperability Agreement With Varian for Dolphin Monitoring
News | Radiation Therapy | October 17, 2018
IBA (Ion Beam Applications S.A.) announced it has entered into an agreement with Varian with the goal of validating the...
Boston Scientific Closes Acquisition of Augmenix Inc.
News | Prostate Cancer | October 17, 2018
Boston Scientific Corp. announced the close of its acquisition of Augmenix Inc., developer of the SpaceOAR Hydrogel...